Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

29 results about "Open reading frame" patented technology

In molecular genetics, an open reading frame (ORF) is the part of a reading frame that has the ability to be translated. An ORF is a continuous stretch of codons that begins with a start codon (usually AUG) and ends at a stop codon (usually UAA, UAG or UGA). An ATG codon (AUG in terms of RNA) within the ORF (not necessarily the first) may indicate where translation starts. The transcription termination site is located after the ORF, beyond the translation stop codon. If transcription were to cease before the stop codon, an incomplete protein would be made during translation. In eukaryotic genes with multiple exons, introns are removed and exons are then joined together after transcription to yield the final mRNA for protein translation. In the context of gene finding, the start-stop definition of an ORF therefore only applies to spliced mRNAs, not genomic DNA, since introns may contain stop codons and/or cause shifts between reading frames. An alternative definition says that an ORF is a sequence that has a length divisible by three and is bounded by stop codons. This more general definition can also be useful in the context of transcriptomics and/or metagenomics, where start and/or stop codon may not be present in the obtained sequences. Such an ORF corresponds to parts of a gene rather than the complete gene.

Dengue and / or zika virus genetically engineered vaccine and preparation method and application thereof

PendingCN122325618AOpen reading frameStructural protein
This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Pharmaceutical composition for treating cancer

PCT designated stageWO2026127065A1Organic active ingredientsGenetic material ingredientsOpen reading framePharmacy medicine
The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.
Owner:NAT UNIV ASAHIKAWA MEDICAL UNIV +1

Messenger RNA with heterologous untranslated regions for enhanced expression and uses thereof

PCT designated stageWO2026143047A1HeterologousOpen reading frame
Disclosed herein are a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a protein of interest, a heterologous 5' untranslated region (UTR) and / or a heterologous 3' UTR for highly expressing the protein of interest. A method for synthesizing the mRNA and uses of the mRNA are also provided.
Owner:DEV CENT FOR BIOTECHNOLOGY +1

Ultrasensitive assays for detection of ORF1p in biofluids

Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +4

Organ fibrosis-related micropeptide ofmp and application thereof

PendingCN122295355AOpen reading frameNucleotide
This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD

A micropeptide, nucleic acids encoding the same and use in modulating microglial inflammatory activation

PendingCN122277693ASmall molecular weightgood biocompatibilityDiseaseOpen reading frame
This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.
Owner:SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL

Modulation of SPP1 gene and OPN protein expression, methods and applications thereof

PCT designated stageWO2026142966A1Open reading frameDouble strand
An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.
Owner:PAINE THERAPEUTICS INC +1

Methods of predicting tumor neoantigens of endogenous retroviral origin

PendingCN122177210AMedical data miningProteomicsOpen reading frameWhite blood cell
This invention provides a method for mining tumor antigens derived from endogenous retroviruses. The method involves bulk RNA-seq sequencing of tumor tissue and adjacent normal tissue samples using a splicing strategy to obtain DNA sequences of human endogenous retrovirus (HERV)-derived transcripts (hervRNA). Subsequently, a specific screening strategy is employed to obtain candidate open reading frames (ORF) sequences on tumor-specific hervRNAs. Finally, homology analysis, prediction of binding energy to human leukocyte antigen class I (HLA-I) molecules, and multi-site analysis are used to predict and mine neoantigens derived from HERV in tumors.
Owner:SHANGHAI JIAOTONG UNIV

Messenger RNA with heterologous untranslated regions for enhanced expression and uses thereof

PendingUS20260176597A1Peptide/protein ingredientsDigestive systemHeterologousOpen reading frame
Disclosed herein are a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a protein of interest, a heterologous 5′ untranslated region (UTR) and / or a heterologous 3′ UTR for highly expressing the protein of interest. A method for synthesizing the mRNA and uses of the mRNA are also provided.
Owner:DEV CENT FOR BIOTECHNOLOGY

Broad-spectrum antibacterial peptide and application thereof

This invention relates to the field of biomedical technology and discloses a broad-spectrum antimicrobial peptide and its applications. The invention obtains a broad-spectrum antimicrobial peptide H by mining non-classical open reading frames (ncORFs) in the human genome. Experimental verification shows that the broad-spectrum antimicrobial peptide H has significant inhibitory effects on both Gram-positive bacteria (Staphylococcus aureus ATCC 29213) and Gram-negative bacteria (Escherichia coli K88). Furthermore, the broad-spectrum antimicrobial peptide H can form an α-helix. The α-helix structure projection diagram shows that one side is rich in positively charged hydrophilic amino acid residues, and the other side is rich in hydrophobic amino acid residues, exhibiting good amphiphilicity. In addition, the broad-spectrum antimicrobial peptide H provided by this invention has low hemolytic activity and no cytotoxicity, ensuring in vivo safety while achieving highly efficient bactericidal activity. It also features a short synthetic sequence, small molecular weight, and is easy to chemically synthesize.
Owner:ZHEJIANG UNIV

Mycobacterium abscessus phage wst2, formulations and uses

PendingCN122278782AOpen reading frameCladobotryum mycophilum
This application discloses Mycobacterium abscessus phage WST2, its formulation, and applications, belonging to the field of microbial technology. This phage, named as a phage belonging to the family Long-tailed Phagecaceae in the order Caudata, is deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC NO: M 2026261. The genome of phage WST2 is a full-length double-stranded DNA of 39,800 bp–40,300 bp, with a G+C content of 60%–65% and containing 50–70 open reading frames. The formulation includes the aforementioned Mycobacterium abscessus phage WST2. Applications include drug preparation, inhibition or elimination of Mycobacterium abscessus, addition to liquids, attachment to object surfaces, or placement inside objects. This application can accurately identify and bind to the surface receptors of Mycobacterium abscessus, effectively lysing clinical strains of Mycobacterium abscessus, thereby inhibiting or eliminating clinical strains of Mycobacterium abscessus.
Owner:SICHUAN UNIV

Application of wheat TaMIPS gene in resistance to Fusarium head blight and stem rot

ActiveCN120290541BBiotechnologyOpen reading frame
This invention discloses the application of the wheat gene TaMIPS in regulating resistance to Fusarium head blight and stem rot. Through the creation of wheat materials, it was demonstrated that overexpression of the TaMIPS gene significantly enhances wheat resistance to Fusarium head blight and stem rot, while mutants exhibit decreased disease resistance. Furthermore, this invention utilizes gene editing technology to optimize the promoter region of the TaMIPS gene, removing the inhibitory effect of the upstream non-coding open reading frame (uORF) on its expression, thereby significantly increasing the expression level of the TaMIPS gene-encoded protein and effectively enhancing wheat disease resistance.
Owner:NANJING AGRICULTURAL UNIVERSITY

A method for preparing smegglutinin using circRNA and related compositions

This invention relates to the field of biopharmaceutical technology, and discloses a method for preparing smegglutinin using circRNA and related compositions. The circRNA molecule contains an open reading frame and an internal ribosome entry site sequence. A recombinant plasmid containing a T7 promoter, introns, and coding sequences is constructed and linearized. A linear RNA intermediate is obtained through in vitro transcription; subsequently, it is placed in a circularization buffer for self-splicing and circularization; and purified to obtain the circRNA molecule stock solution. The related pharmaceutical composition contains circRNA molecules, a four-component lipid mixture, and excipients containing carbohydrates and nonionic surfactants. This invention constructs circRNA molecules with closed-loop structures and utilizes the internal ribosome entry site sequence to initiate translation. The lack of ends in the closed-loop structure avoids exonuclease degradation, thus prolonging the protein expression cycle, improving the purity of the stock solution, and reducing the risk of immune responses caused by linear RNA impurities.
Owner:SHAANXI WEIJI BIOTECHNOLOGY CO LTD

Peanut plant type regulation gene ah erect1 and its mutants and application

PendingCN122357582ABiotechnologyOpen reading frame
This invention belongs to the fields of molecular genetics and genetic engineering, and discloses a peanut plant type regulating gene, AhERECT1, its mutants, and their applications. The nucleotide sequence of the peanut plant type regulating gene AhERECT1 is shown in SEQ ID NO.1. Its mutant is caused by a single amino acid deletion due to the deletion of nucleotides 38-40 (CTC) in the open reading frame of the gene shown in SEQ ID NO.1, and its nucleotide sequence is shown in SEQ ID NO.2. This invention obtained the AhERECT1 gene through linkage mapping, fine mapping, and transcriptome analysis. Using CRISPR / Cas9 gene editing technology, the erect peanut variety Yuhua 9326 was successfully modified into a semi-vine type through targeted editing. The gene and its mutants of this invention provide key gene resources and efficient technical support for the precise improvement of peanut plant type, and can be widely applied to the breeding of peanut varieties with different plant types, which is of great significance for improving peanut yield and quality.
Owner:HENAN ACAD OF AGRI SCI

Cancer antigens

PendingJP2026518273AOrganic active ingredientsTumor rejection antigen precursorsDiseaseCancer prevention
The present invention relates to tumor antigens or cancer antigens, particularly amino acid sequences and nucleic acid sequences, which may be used in cancer immunotherapy. In particular, the present invention relates to artificial nucleic acids, preferably RNA, comprising at least one coding sequence encoding at least one tumor antigen or cancer antigen. The tumor antigen or cancer antigen is Peptides or proteins encoded by small open reading frames (smORFs) of long non-coding RNA (IncRNA), or The fragment or variant thereof, At least one antigenic peptide selected from or derived therefrom, and / or Tumor neoantigen peptides or proteins, or The fragment or variant thereof, at least one antigenic peptide selected from or derived therefrom The invention provides a pharmaceutical composition comprising or consisting of the artificial nucleic acid, preferably formulated within a lipid-based carrier. It also provides a method for treating or preventing a disease, disorder, or condition, and medical applications for treating or preventing cancer in particular (such as NSCLC, HNSCC, or melanoma).
Owner:CUREVAC SE

Chitin synthase 1 (LmCHS1) gene, its dsRNA, its synthesis method, and its insect resistance application in the leafminer moth.

This invention discloses the chitin synthase 1 (LmCHS1) gene of the leafminer moth, its dsRNA, its synthesis method, and its insect-resistant applications. Through transcriptome analysis, specific primer pairs for the open reading frame of the LmCHS1 gene were designed and synthesized. The LmCHS1 gene sequence was obtained through gene cloning (nucleotide sequence: SEQ ID NO: 1, amino acid sequence: SEQ ID NO: 2). The gene fragment with sequence SEQ ID NO: 3 was selected as the RNAi target sequence. Primer pairs SEQ ID NO: 6 and SEQ ID NO: 7 with restriction enzyme sites were designed and synthesized. PCR amplification was performed, and a prokaryotic expression vector was constructed to induce dsRNA expression. Feeding leafminer moth larvae with dsRNA interfered with LmCHS1 gene expression. After 24 hours, abnormalities were observed in the larvae's body surface, with some larvae failing to complete molting or dying due to an inability to form a normal body surface after molting. After 96 hours, the larval mortality rate was 72.22%, compared to 40% in the GFP control group, demonstrating a significant effect. This invention has broad application prospects in the control of the leaf borer pest in forestry due to its high efficiency, specificity, and safety.
Owner:NORTHEAST FORESTRY UNIV

UBE3A genes and expression cassettes and their use

PendingAU2020279387B2Abnormal expressionOpen reading frame
This invention relates to polynucleotides comprising UBE3A open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a UBE3A gene or aberrant activity of a UBE3A gene product in the subject, such as Angelman Syndrome.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Downregulation of a reduced yield transgene expressed by a poxvirus

PendingCN122349568ABiotechnologyOpen reading frame
The present invention relates to recombinant poxviruses comprising a binding sequence for a transcriptional repressor protein, such as a tetracycline repressor protein, located between a poxvirus promoter and the open reading frame (ORF) of a yield-reducing transgene, and to transgenic poxvirus producer cells expressing the corresponding repressor protein.
Owner:BAVARIAN NORDIC AS

Multi-antigen tandem mRNA lung cancer vaccine and application thereof in preparation of antitumor drugs

PendingCN122251565AMicroencapsulation basedNanomedicineAntigen epitopeOpen reading frame
The present application relates to the technical field of mRNA vaccine, in particular to a multi-antigen tandem mRNA lung cancer vaccine and its application in the preparation of an anti-tumor drug, comprising an mRNA molecule and a lipid nanoparticle encapsulating the mRNA, the mRNA sequentially comprises a cap structure, a 5' untranslated region, an open reading frame, a 3' untranslated region and a polyA tail from 5' end to 3' end, the open reading frame encodes a fusion antigen protein, which sequentially comprises a signal peptide, a lung cancer shared mutant antigen module, a tumor associated antigen module and a MHC-I directed transport domain, each antigen fragment is connected by an AAY connecting peptide, and the lipid nanoparticle is composed of ionized lipids, cholesterol, auxiliary phospholipids and PEG-lipids. The present application takes into account antigen specificity and coverage, can efficiently release antigen epitopes, improve antigen presentation efficiency, strongly activate specific anti-tumor immunity, adapt a stable delivery system, and has a good application prospect in lung cancer treatment.
Owner:JIANGSU OCEAN UNIV

Compositions and methods for treatment of cancer

PendingUS20260152745A1Organic active ingredientsAntineoplastic agentsOpen reading frameOncology
The present application features methods of treating cancer by administering a polynucleotide that reduces expression of a dysregulated novel open reading frame (nORF) in which increased expression of the dysregulated nORF is associated with the cancer.
Owner:NONEXOMICS INC

Preparation method of artificial defective interfering RNA and application thereof in anti-cucumber mosaic virus

PendingCN122104711AVector-based foreign material introductionAngiosperms/flowering plantsOpen reading frameCucumber mosaic virus
The application belongs to the technical field of biology, and particularly relates to a preparation method of artificial defective interfering RNA and application thereof in resisting cucumber mosaic virus. The application discloses an artificial defective interfering RNA, which comprises the following elements in the direction from the 5' end to the 3' end: a 5' end UTR of a CMV genomic RNA3, an IGR, a CP open reading frame and a 3' end UTR sequence. The application also simultaneously provides a recombinant DNA for coding the artificial defective interfering RNA. The application also simultaneously provides a recombinant expression vector containing the above-mentioned recombinant DNA. The application also simultaneously provides application of the above-mentioned artificial defective interfering RNA, the recombinant DNA and the recombinant expression vector in resisting cucumber mosaic virus.
Owner:ZHEJIANG SCI-TECH UNIV

Immunogenic compositions and uses thereof

PendingUS20260166136A1Antibacterial agentsWhole-cell/virus/DNA/RNA ingredientsOpen reading frameUpper urinary tract infection
The invention relates to compositions comprising two or more ribonucleic acid (RNA) polynucleotides comprising an open reading frame (ORF) encoding at least one Eschericia coli (E. coli) fimbrial antigen polypeptide or an immunogenic fragment thereof, wherein the RNA polynucleotide encodes fimbrial antigen H (FimH) protein and / or PapG protein and is formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Owner:PFIZER INC

A CagW mRNA-LNP composition and its application in the preparation of products for treating Helicobacter pylori infection.

PendingCN122297652ADiseaseOpen reading frame
This invention relates to a Cag W mRNA-LNP composition and its application in the preparation of products for treating Helicobacter pylori infection. The composition comprises (i) mRNA encoding an open reading frame of Cag W protein or an immunogenic fragment thereof; and (ii) an LNP nanoparticle delivery carrier. The sequence of the mRNA encoding Cag W protein is shown in SEQ ID NO. 1 and 3, and the amino acid sequence is shown in SEQ ID NO. 2 and 4. Compared with the prior art, the Cag W mRNA-LNP vaccine prepared by this invention has high immunogenicity, targeting, potent humoral immunity, comprehensive and ideal cellular immunity, 100% challenge protection efficacy, and effective bacterial clearance.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for improved AAV production

PCT designated stageWO2026109693A1Virus peptidesAnimals/human peptidesOpen reading frameCapsid
The present invention relates to methods for producing preparations comprising recombinant adeno-associated virus (rAAV) particles. More particularly, the present invention relates to methods for producing a preparation comprising recombinant adeno-associated virus (rAAV) particles wherein an Open Reading Frame (ORF) is introduced to a host cell under suitable conditions, so that said ORF is overexpressed, and wherein said preparation comprises rAAV particles have improved and / or increased viral genome titer, capsid titer, and / or functional titer. The disclosure also provides preparations comprising recombinant adeno-associated virus (rAAV) particles having improved and / or increased viral genome titer, capsid titer, and / or functional titer.
Owner:ASCEND ADVANCED THERAPIES LTD

Immunogenic compositions and uses thereof

PCT designated stageWO2026133156A1Antibacterial agentsAntibody medical ingredientsOpen reading frameUpper urinary tract infection
The invention relates to compositions comprising two or more ribonucleic acid (RNA) polynucleotides comprising an open reading frame (ORF) encoding at least one Eschericia coli (E.coli) fimbrial antigen polypeptide or an immunogenic fragment thereof, wherein the RNA polynucleotide encodes fimbrial antigen H (FimH) protein and / or PapG protein and is formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Owner:PFIZER INC

RNA molecule for use in controlled translation

PCT designated stageWO2026141684A1Open reading frameProtein target
The present invention provides an RNA molecule comprising: an open reading frame comprising a sequence which encodes a desired protein; an aptamer domain able to bind with a protein (target protein) different from the desired protein; and a short-chain single-stranded nucleic acid target domain comprising a target sequence with which a short-chain single-stranded nucleic acid can bind.
Owner:CHUGAI PHARMA CO LTD

Application of circEPB41L5 molecule and polypeptide coded by circEPB41L5 molecule in preparation of medicine for inhibiting proliferation of cholangiocarcinoma and recombinant cell

PendingCN122075670APeptide/protein ingredientsDigestive systemOpen reading frameAmino acid
The invention relates to the field of biological pharmacy, in particular to application of circEPB41L5 molecules and polypeptides coded by the circEPB41L5 molecules in preparation of drugs for inhibiting proliferation of bile duct cancer and a recombinant cell. The nucleotide sequence of the circular RNA molecule circEPB41L5 is SEQ ID NO: 1, the amino acid sequence of a development reading frame of polypeptide coded by the circular RNA molecule circEPB41L5 is SEQ ID NO: 2, the AMPK / mTOR pathway is jointly regulated and controlled by interacting with IRS-1 protein, then bile duct cancer cell autophagy is induced, the proliferation, migration and invasion ability of bile duct cancer cells is inhibited, and a new thought is provided for treatment of bile duct cancer.
Owner:SUZHOU UNIV

Application of cmcad1 gene in lignin synthesis and regulation of plant salt resistance

PendingCN122168638AOxidoreductasesFermentationBiotechnologyOpen reading frame
This invention belongs to the field of plant genetic engineering technology, specifically involving CmCAD1 The application of genes in lignin synthesis and regulation of plant salt tolerance. CmCAD1 The nucleotide sequence of the gene corresponds to cinnamyl alcohol dehydrogenase, with an open reading frame of 1068 bp encoding 356 amino acids. This invention has confirmed through functional verification that… CmCAD1 This gene can positively regulate the biosynthesis of lignin in plants, controlling stem cell wall thickness, lignin content, and stem mechanical strength. Simultaneously, this gene can significantly enhance the antioxidant capacity, osmotic regulation capacity, and cell membrane stability of plants under salt stress, positively regulating plant salt tolerance. Utilizing this invention... CmCAD1 Genes can be used to breed new plant varieties with optimized lignin content, improved stem mechanical strength, and enhanced salt tolerance. They are particularly suitable for molecular breeding of plants in the Asteraceae family, such as chrysanthemums, and have important application value in fields such as saline-alkali land agriculture and stress-resistant breeding in the flower industry.
Owner:HENAN UNIVERSITY